HDAC9 and cancer: Practically, the Food and Drug Administration accepted two Hdac inhibitors suberoylanilide hydroxamic acid (SAHA) and FK-228 for the treatment of cutaneous T-cell lymphoma, and several Hdac inhibitors are in phase I or II of clinical trials in cancer patients (Monneret 2005).